Chordia Therapeutics Inc. (190A) Press Release
Announcement Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of rogocekib
Filed with TSE ·
6ix hasn’t read this filing yet.
Earlier from Chordia Therapeutics
- Announcement of Orphan Drug Designation in Japan for rogocekib for Relapsed or Refractory AML
- Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor
- Notice of Receipt of Grant
- Non-consolidated Financial Results for the Nine Months Ended May 31 2026 [Japanese GAAP]